Oxford BioMedica PLC - ESG Rating & Company Profile powered by AI
Comprehensive ESG assessment of Oxford BioMedica PLC can be reached by signing in. The webpage includes a Q&A table about Oxford BioMedica PLC. The report of Oxford BioMedica PLC incorporates data points from across the internet as well as from available documents by Oxford BioMedica PLC.
Oxford BioMedica PLC in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 7.5; made up of an environmental score of 8.0, social score of 6.4 and governance score of 8.0.
7.5
High ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 209 | WuXi AppTec Co Ltd | 7.6 | High |
| 209 | Waters Corp | 7.6 | High |
| 256 | Oxford BioMedica PLC | 7.5 | High |
| 256 | Acorda Therapeutics Inc | 7.5 | High |
| 256 | Alkermes Plc | 7.5 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Oxford BioMedica PLC have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Oxford BioMedica PLC disclose current and historical energy intensity?
Sign up for free to unlockDoes Oxford BioMedica PLC report the average age of the workforce?
Sign up for free to unlockDoes Oxford BioMedica PLC reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Oxford BioMedica PLC disclose its ethnicity pay gap?
Sign up for free to unlockDoes Oxford BioMedica PLC disclose cybersecurity risks?
Sign up for free to unlockDoes Oxford BioMedica PLC offer flexible work?
Sign up for free to unlockDoes Oxford BioMedica PLC have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Oxford BioMedica PLC disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Oxford BioMedica PLC conduct supply chain audits?
Sign up for free to unlockDoes Oxford BioMedica PLC disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Oxford BioMedica PLC conduct 360 degree staff reviews?
Sign up for free to unlockDoes Oxford BioMedica PLC disclose the individual responsible for D&I?
Sign up for free to unlockDoes Oxford BioMedica PLC disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Oxford BioMedica PLC disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Oxford BioMedica PLC disclose water use targets?
Sign up for free to unlockDoes Oxford BioMedica PLC have careers partnerships with academic institutions?
Sign up for free to unlockDid Oxford BioMedica PLC have a product recall in the last two years?
Sign up for free to unlockDoes Oxford BioMedica PLC disclose incidents of discrimination?
Sign up for free to unlockDoes Oxford BioMedica PLC allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Oxford BioMedica PLC issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Oxford BioMedica PLC disclose parental leave metrics?
Sign up for free to unlockDoes Oxford BioMedica PLC disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Oxford BioMedica PLC disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Oxford BioMedica PLC disclose the pay ratio of women to men?
Sign up for free to unlockDoes Oxford BioMedica PLC support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Oxford BioMedica PLC disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Oxford BioMedica PLC reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Oxford BioMedica PLC involved in embryonic stem cell research?
Sign up for free to unlockDoes Oxford BioMedica PLC disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Oxford BioMedica PLC disclose its waste policy?
Sign up for free to unlockDoes Oxford BioMedica PLC report according to TCFD requirements?
Sign up for free to unlockDoes Oxford BioMedica PLC disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Oxford BioMedica PLC disclose energy use targets?
Sign up for free to unlockDoes Oxford BioMedica PLC disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Oxford BioMedica PLC have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Oxford BioMedica PLC
These potential risks are based on the size, segment and geographies of the company.
Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates various therapeutic genes. The company's products under development stage include Axo-Lenti-PD, a gene-based treatment for parkinson's disease; OXB-302, which is in pre-clinical stage for the treatment of haematological tumours; OXB-401 that is in pre-clinical stage for the treatment of liver indication; OXB-40X for liver indication; and OXB-40Y for liver indication. The company has partnerships with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Immatics, Arcellx, and Vaccines Manufacturing and Innovation Centre. The company also has a research collaboration agreement with Circularis Biotechnologies to identify novel tissue specific promoters for in vivo lentiviral gene therapy products; Virica Biotech for scaling of viral medicines; Isolere Bio provides a platform technology for tackling downstream inefficiencies in the manufacturing of biologics; and BiologIC Technologies provides novel biocomputer system for viral vector development. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.